Table 1 Baseline demographics and clinical characteristics.

From: Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study

Characteristic

Primary study population: Severe/very severe VOD/SOS post-HCT (N = 251)

Mild/moderate VOD/SOS post-HCT (N = 81)

Median (range) age at HCT, years

45 (0, 74)

35 (0, 69)

Age group, n/N (%)

  <18 years

58/251 (23)

29/81 (36)

  ≥18 years

193/251 (77)

52/81 (64)

Primary disease,a n/N (%)

  AML

68/251 (27)

20/81 (25)

  ALL

49/251 (20)

16/81 (20)

  Lymphoma

46/251 (18)

10/81 (12)

  MDS/MPS

29/251 (12)

12/81 (15)

Conditioning regimen, n/N (%)

  Myeloablative

135/250 (54)

61/81 (75)

Allogeneic HCT, n/N (%)

220/250 (88)

66/81 (81)

  Unrelated donor

99/220 (45)

34/81 (42)

  Haploidentical donor

41/220 (19)

8/81 (10)

Prophylaxis for GvHD, n/N (%)

218/220 (99)

66/66 (100)

  Sirolimus

4/214 (2)

0

  Cyclophosphamide post-HCT

48/215 (22)

10/65 (15)

Methotrexate

75/215 (35)

29/65 (45)

  1. ALL indicates acute lymphoblastic leukaemia, AML acute myeloid leukaemia, GvHD graft-versus-host disease, HCT haematopoietic cell transplantation, MDS/MPS myelodysplastic syndrome/myeloproliferative syndrome, VOD/SOS veno-occlusive disease/sinusoidal obstruction syndrome.
  2. aPrimary disease indicates those occurring in >10% of patients with severe/very severe VOD/SOS post-HCT (primary study population).
Back to article page